Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir (± Ribavirin) – SODA study
2014-002808-25Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir, daclatasvir and ribavirin in chronic hepatitis C (CHC) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Immune response. Started Nov 2014; status: completed.
02
Drugs
sofosbuvirdaclatasvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-002808-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002808-25.